Perrimustine
Alternative Names: CMSOEN2Latest Information Update: 28 Nov 2007
At a glance
- Originator INSERM
- Class Antineoplastics; Nitrosourea compounds
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Jan 2001 No-Development-Reported for Cancer in France (IV)